Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1,03
KB-0,31
PKN120,8120,85-7,08
Msft0,39
IBM0,86
DCX68,7668,79-0,55
PFE1,14
20.10.2017 1:38:21
Indexy online
AD Index online
select
AD Index online
 

  • 19.10.2017
Xencor (NASDAQ Cons)
Závěr k 19.10.2017 Změna (%) Změna (USD) Objem obchodů (ks)
21,80 -2,98 -0,67 114 751
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 20.10.2017
Popis společnosti
Obecné informace
Název společnostiXencor Inc
TickerXNCR
Kmenové akcie:Ordinary Shares
RICXNCR.O
ISINUS98401F1057
Prioritní akcieConv. Pref. Shrs Series A-1
Prioritní akcieConv. Pref. Shrs Series A-2
Prioritní akcieConv. Pref. Shrs
Prioritní akcieOrdinary Shares
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2016 83
Akcie v oběhu k 1.8.2017 46 926 340
Počet akcionářů k 31.12.2016 226
MěnaUSD
Kontaktní informace
Ulice111 W Lemon Ave
MěstoMONROVIA
PSČ91016-2809
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 263 055 900
Fax16263050350

Business Summary: Xencor, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases. It is also developing a pipeline of bispecific antibody candidates using its heterodimer Fc bispecific technology: XmAb14045, which is in a Phase I trial for the treatment of acute myeloid leukemia (AML); XmAb13676, which is in a Phase I trial for the treatment of B-cell malignancies; XmAb18087, which is in preclinical development for the treatment of neuroendocrine tumors, and XmAb20717, which is in preclinical development for the treatment of various cancers and is its dual checkpoint inhibitor.
Financial Summary: BRIEF: For the six months ended 30 June 2017, Xencor Inc revenues decreased 76% to $17.7M. Net loss totaled $21.5M vs. income of $40.8M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Research and Development - Balancing val increase of 26% to $28.2M (expense), Stock-based Compensation in R&D increase of 76% to $3.7M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 20.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, Founder, DirectorBassil Dahiyat461.1.1997
Senior Vice President, Research and Chief Scientific OfficerJohn Desjarlais52
Senior Vice President, Chief Medical OfficerPaul Foster63
Vice President - FinanceJohn Kuch57
Chief Business OfficerEdgardo Baracchini57